1. Home
  2. AGIG vs GANX Comparison

AGIG vs GANX Comparison

Compare AGIG & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Abundia Global Impact Group Inc. Common stock

AGIG

Abundia Global Impact Group Inc. Common stock

HOLD

Current Price

$0.65

Market Cap

54.3M

Sector

Energy

ML Signal

HOLD

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

SELL

Current Price

$0.98

Market Cap

52.2M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
AGIG
GANX
Founded
N/A
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
54.3M
52.2M
IPO Year
2025
2021

Fundamental Metrics

Financial Performance
Metric
AGIG
GANX
Price
$0.65
$0.98
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
5
Target Price
$4.50
★ $6.60
AVG Volume (30 Days)
73.5K
★ 718.3K
Earning Date
11-09-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 31.46
EPS
★ N/A
N/A
Revenue
★ $410,632.00
$55,180.00
Revenue This Year
$1,689.92
N/A
Revenue Next Year
$36.05
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.45
$0.94
52 Week High
$5.31
$4.34

Technical Indicators

Market Signals
Indicator
AGIG
GANX
Relative Strength Index (RSI) 33.16 39.17
Support Level N/A $0.94
Resistance Level $1.08 $1.91
Average True Range (ATR) 0.08 0.13
MACD -0.02 0.02
Stochastic Oscillator 40.43 16.64

Price Performance

Historical Comparison
AGIG
GANX

About AGIG Abundia Global Impact Group Inc. Common stock

Abundia Global Impact Group Inc. is a technology solutions company operating in recycling, renewable energy, environmental change, fuels, and chemicals sectors, mainly focused on low-carbon energy solutions. The company uses waste plastics and biomass to produce crude or drop-in alternatives to fossil-derived energy, fuels, and chemicals through proprietary, licensed, and commercialized technologies, forming a complete process. It operates through its subsidiary and integrates feedstocks, technology, and off-take partners into a complete commercial chain. Its segments include Oil and Gas (O&G), which generates maximum revenue, and Renewables, which consists of its low-carbon fuels and renewable chemicals business.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.

Share on Social Networks: